Praluent® (alirocumab)

BL 125559

Praluent® (alirocumab)

BL 125559

U.S. License Holder:

Sanofi Aventis

Date of License:

July-24-2015

Last Update:

October-15-2019

approved_indications FDA-Approved Indications

PRALUENT (alirocumab) is a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody indicated:

To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease;

As adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol LDL-C.

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:14-cv-01317 (D. Del.)

U.S. Patent Nos.
8,563,698 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,829,165 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,859,741 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,871,913 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,871,914 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,883,983 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,889,834 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))

Plaintiffs
Amgen Inc.; Amgen Manufacturing, Ltd.; Amgen USA, Inc.

Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC

Federal Circuit Appeal(s)
17-1480

Supreme Court Appeal(s)
18-127

Status
District Court Determination that Patents Valid and Infringed; Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding for New Trial on Written Description and Enablement; Petition for Rehearing En Banc Denied; Supreme Court Writ of Certiorari Denied; On Remand Jury Found Three Claims Not Invalid and Two Claims Invalid for Lack of Written Description, Defendant's Motion for JMOL Denied as to Written Description but Granted as to Enablement, Motion for New Trial Denied, Motion for Permanent Injunction Denied as Moot because Claims Not Enabled

BPCIA
N

1:14-cv-01349 (D. Del.)

U.S. Patent Nos.
8,871,913 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)) 8,871,914 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))

Plaintiffs
Amgen Inc.

Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC

Federal Circuit Appeal(s)
17-1480

Supreme Court Appeal(s)
18-127

Status
Consolidated with 1:14-cv-01317 (D. Del.); Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding in Lead Case (1:14-cv-01317; Fed. Cir. 2017-1480); Supreme Court Writ of Certiorari Denied; On Remand Jury Found Three Claims Not Invalid and Two Claims Invalid for Lack of Written Description, Defendant's Motion for JMOL Denied as to Written Description but Granted as to Enablement, Motion for New Trial Denied, Motion for Permanent Injunction Denied as Moot because Claims Not Enabled

BPCIA
N

1:14-cv-01393 (D. Del.)

U.S. Patent Nos.
8,883,983 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))

Plaintiffs
Amgen Inc.

Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC

Federal Circuit Appeal(s)
17-1480

Supreme Court Appeal(s)
18-127

Status
Consolidated with 1:14-cv-01317 (D. Del.); Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding in Lead Case (1:14-cv-01317; Fed. Cir. 2017-1480); Supreme Court Writ of Certiorari Denied; On Remand Jury Found Three Claims Not Invalid and Two Claims Invalid for Lack of Written Description, Defendant's Motion for JMOL Denied as to Written Description but Granted as to Enablement, Motion for New Trial Denied, Motion for Permanent Injunction Denied as Moot because Claims Not Enabled

BPCIA
N

1:14-cv-01414 (D. Del.)

U.S. Patent Nos.
8,889,834 (Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9))

Plaintiffs
Amgen Inc.

Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi; Sanofi-Aventis US LLC; Aventisub LLC

Federal Circuit Appeal(s)
17-1480

Supreme Court Appeal(s)
18-127

Status
Consolidated with 1:14-cv-01317 (D. Del.); Federal Circuit Decision Reversing-In-Part, Affirming-In-Part, Vacating-In-Part, and Remanding in Lead Case (1:14-cv-01317; Fed. Cir. 2017-1480); Supreme Court Writ of Certiorari Denied; On Remand Jury Found Three Claims Not Invalid and Two Claims Invalid for Lack of Written Description, Defendant's Motion for JMOL Denied as to Written Description but Granted as to Enablement, Motion for New Trial Denied, Motion for Permanent Injunction Denied as Moot because Claims Not Enabled

BPCIA
N

2:15-cv-05685 (C.D. Cal.)

U.S. Patent Nos.
7,923,221 (Methods of Making Antibody Heavy and Light Chains having Specificity for a Desired Antigen)

Plaintiffs
Regeneron Pharmaceuticals, Inc.; Sanofi-Aventis US LLC

Defendants
City of Hope; Genentech, Inc.

Status
Dismissed

BPCIA
N

related articles Related News Articles

Venable Fitzpatrick’s BiologicsHQ Monthly Injection – February 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. March 6, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – January 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. February 11, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – July 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. August 3, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – February 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. March 6, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – December 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. January 8, 2018
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – October 2017 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. November 3, 2017

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

captcha